Low Risk of Hepatocellular Carcinoma in Patients With Primary Sclerosing Cholangitis With Cirrhosis

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 10, 2014, Pages 1733-1738

  Zenouzi, Roman ^a   Weismüller, Tobias J ^b,c   Hübener, Peter ^a   Schulze, Kornelius ^a   Bubenheim, Michael ^d   Pannicke, Nadine ^a   Weiler Normann, Christina ^a   Lenzen, Henrike ^c   Manns, Michael P ^c   Lohse, Ansgar W ^a   Schramm, Christoph ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d HÔPITAL CHARLES NICOLLE   (France)

Author keywords

AIH; Cholangiocarcinoma; Liver Cancer; Population; Screening

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; ASCITES; BILE DUCT CARCINOMA; CANCER RISK; CHILD; COLORECTAL CANCER; CROHN DISEASE; DISEASE COURSE; ELASTOGRAPHY; ESOPHAGUS VARICES; EXPLANT; FEMALE; GALLBLADDER CANCER; GERMANY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INCIDENTAL FINDING; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIMARY SCLEROSING CHOLANGITIS; RETROSPECTIVE STUDY; TERTIARY CARE CENTER; ULCERATIVE COLITIS; BIOSTATISTICS; CARCINOMA, HEPATOCELLULAR; COMPLICATION; INCIDENCE; LIVER NEOPLASMS; MIDDLE AGED; PRESCHOOL CHILD; RISK ASSESSMENT; SCLEROSING CHOLANGITIS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOSTATISTICS; CARCINOMA, HEPATOCELLULAR; CHILD; CHILD, PRESCHOOL; CHOLANGITIS, SCLEROSING; FEMALE; GERMANY; HUMANS; INCIDENCE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TERTIARY CARE CENTERS; YOUNG ADULT;

EID: 84908096442     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.02.008     Document Type: Article

References (31)

1. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. JHepatol 2009, 51:237-267. European Association for the Study of the Liver.
2. Tischendorf J.J., Hecker H., Kruger M., et al. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. Am J Gastroenterol 2007, 102:107-114.
3. Razumilava N., Gores G.J., Lindor K.D. Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology 2011, 54:1842-1852.
4. Bergquist A., Ekbom A., Olsson R., et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. JHepatol 2002, 36:321-327.
5. Boonstra K., Weersma R.K., van Erpecum K.J., et al. Population-based epidemiology, malignancy risk and outcome of primary sclerosing cholangitis. Hepatology 2013, 58:2045-2055.
6. Schramm C., Lohse A.W. Gallbladder polyps in primary sclerosing cholangitis: indication for early intervention. Hepatology 2012, 56:396. author reply.
7. Claessen M.M., Vleggaar F.P., Tytgat K.M., et al. High lifetime risk of cancer in primary sclerosing cholangitis. JHepatol 2009, 50:158-164.
8. Leidenius M.H., Farkkila M.A., Karkkainen P., et al. Colorectal dysplasia and carcinoma in patients with ulcerative colitis and primary sclerosing cholangitis. Scand J Gastroenterol 1997, 32:706-711.
9. Chen C.J., Yang H.I., Su J., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295:65-73.
10. Degos F., Christidis C., Ganne-Carrie N., et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000, 47:131-136.
11. Beaton M.D., Adams P.C. Prognostic factors and survival in patients with hereditary hemochromatosis and cirrhosis. Can J Gastroenterol 2006, 20:257-260.
12. Elmberg M., Hultcrantz R., Ekbom A., et al. Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology 2003, 125:1733-1741.
13. Teufel A., Weinmann A., Centner C., et al. Hepatocellular carcinoma in patients with autoimmune hepatitis. World J Gastroenterol 2009, 15:578-582.
14. Yeoman A.D., Al-Chalabi T., Karani J.B., et al. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: implications for follow-up and screening. Hepatology 2008, 48:863-870.
15. Farinati F., Floreani A., De Maria N., et al. Hepatocellular carcinoma in primary biliary cirrhosis. JHepatol 1994, 21:315-316.
16. Chapman R., Fevery J., Kalloo A., et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010, 51:660-678.
17. Eaton J.E., Talwalkar J.A., Lazaridis K.N., et al. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology 2013, 145:521-536.
18. Harnois D.M., Gores G.J., Ludwig J., et al. Are patients with cirrhotic stage primary sclerosing cholangitis at risk for the development of hepatocellular cancer?. JHepatol 1997, 27:512-516.
19. Bruix J., Sherman M. American Association for the Study of Liver Disease: Management of hepatocellular carcinoma: an update. Hepatology 2011, 53:1020-1022.
20. Corpechot C., El Naggar A., Poujol-Robert A., et al. Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology 2006, 43:1118-1124.
21. Piantadosi S. Clinical trials: a methodologic perspective 2005, 262. Wiley, Hoboken, NJ.
22. Boberg K.M., Lind G.E. Primary sclerosing cholangitis and malignancy. Best Pract Res Clin Gastroenterol 2011, 25:753-764.
23. Denzer U., Arnoldy A., Kanzler S., et al. Prospective randomized comparison of minilaparoscopy and percutaneous liver biopsy: diagnosis of cirrhosis and complications. JClin Gastroenterol 2007, 41:103-110.
24. Corpechot C., Gaouar F., El Naggar A., et al. Baseline values and changes in liver stiffness, measured by transient elastography, are associated with fibrosis severity and outcomes of patients with primary sclerosing cholangitis. Gastroenterology 2014, 146:970-979.
25. White D.L., Kanwal F., El-Serag H.B. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol 2012, 10:1342-1359.e2.
26. Demarchi B., Bresso F., Novero D., et al. Hepatocellular carcinoma complicating primary sclerosing cholangitis in Crohn's disease. A case report. Minerva Gastroenterol Dietol 2007, 53:279-283.
27. Luth S., Schrader J., Zander S., et al. Chronic inflammatory IFN-gamma signaling suppresses hepatocarcinogenesis in mice by sensitizing hepatocytes for apoptosis. Cancer Res 2011, 71:3763-3771.
28. Dunn G.P., Koebel C.M., Schreiber R.D. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006, 6:836-848.
29. Soetikno R.M., Lin O.S., Heidenreich P.A., et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002, 56:48-54.
30. Broome U., Lofberg R., Veress B., et al. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 1995, 22:1404-1408.
31. de Valle M.B., Bjornsson E., Lindkvist B. Mortality and cancer risk related to primary sclerosing cholangitis in a Swedish population-based cohort. Liver Int 2012, 32:441-448.